Literature DB >> 10574680

Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4.

J K Coller1, A A Somogyi, F Bochner.   

Abstract

The aims were to examine the kinetics of the oxidative metabolism of flunitrazepam in vitro when flunitrazepam was dissolved in dimethylformamide and acetonitrile, and to determine which cytochrome P450 isoform(s) are involved. The kinetics of the formations of 3'-hydroxyflunitrazepam and desmethyl-flunitrazepam were non-linear and best estimated using the Hill equation. Inhibition of their formation was studied using specific chemical inhibitors, expressed enzyme systems and specific antibodies. Ks, Vmax, Clmax and n (slope factor) for the formation of 3'-hydroxyflunitrazepam and desmethylflunitrazepam had ranges of 165-338 and 179 391 microM, 22-81 and 3-10 nmol x mg protein(-1) x h(-1), 6-17 and 0.9-1.9 microl x mg protein(-1) x h(-1), and 2.3-3.6 and 1.6-2.6 respectively when dimethylformamide was the organic solvent. When acetonitrile was the solvent, Ks, Vmax, Clmax and n (slope factor) for the formation of 3'-hydroxyflunitrazepam and desmethylflunitrazepam had ranges of 173-231 and 74-597 microM, 35-198 and 2.7-48 nmol.mg protein(-1) x h(-1), 1347 and 0.7-6.3 microl.mg protein(-1) x h(-1), and 1.5-3.6 and 1.1-2.7 respectively. CYP2C19, CYP3A4 and CYP1A2 mediated the formation of both 3'-hydroxyflunitrazepam and desmethylflunitrazepam. Investigators need carefully to consider the choice of organic solvent to avoid false CYP identification.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10574680     DOI: 10.1080/004982599238056

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  6 in total

1.  The xenobiotic inhibitor profile of cytochrome P4502C8.

Authors:  C E Ong; S Coulter; D J Birkett; C R Bhasker; J O Miners
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

Authors:  Mark R Hutchinson; Andrew Menelaou; David J R Foster; Janet K Coller; Andrew A Somogyi
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

Review 4.  Pharmacogenetics of anxiolytic drugs.

Authors:  Arun K Tiwari; Renan P Souza; Daniel J Müller
Journal:  J Neural Transm (Vienna)       Date:  2009-05-12       Impact factor: 3.575

Review 5.  Metabolites replace the parent drug in the drug arena. The cases of fonazepam and nifoxipam.

Authors:  Maria Katselou; Ioannis Papoutsis; Panagiota Nikolaou; Chara Spiliopoulou; Sotiris Athanaselis
Journal:  Forensic Toxicol       Date:  2016-09-17       Impact factor: 4.096

Review 6.  Pharmaceutical Excipients and Drug Metabolism: A Mini-Review.

Authors:  Rahul Patel; James Barker; Amr ElShaer
Journal:  Int J Mol Sci       Date:  2020-11-03       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.